BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Fuse Science Set to Redefine $3.0 Billion Patch Market with Roll-On Application Technology


10/24/2012 8:47:48 AM

MIAMI LAKES, Fla., Oct. 23, 2012 /PRNewswire/ -- Fuse Science, Inc. (OTCQB: DROP) (www.fusescience.com), an innovative company that possesses proprietary delivery technology set to redefine how consumers receive energy, medicines, vitamins and minerals, today provides further insight into the numerous potential applications of their technology arising from their most recent scientific testing research results.

The conclusions of the research documented that the Company can deliver a wide range of compounds successfully through the epidermis in a simple roll-on application. This proprietary patchless delivery technology represents what the Company believes to be a major paradigm shift in the $3.0 billion dollar global patch market, which is growing at approximately 12% annually. Fuse believes that the ability to eliminate the need for a consumer or patient to wear a patch on the skin for extended compound delivery eliminates the frustration experienced by many consumers in having to wear a patch.

"These science results indicate that Fuse Science possesses capabilities to significantly enhance delivery and convenience with the application of our proprietary technology," said Jeanne Hebert, Fuse Science, Vice President of Marketing and Clinical Research. "Being able to provide effective therapy, without requiring the patient to wear a patch throughout the day, is of major benefit to the consumer. Our previously announced licensing and M&A efforts coordinated by Atlas Advisors (www.atlasadvisors.com) are designed to specifically enable structured talks with the leading manufacturers in the growing $3.0 billion patch industry."

Many of these compounds researched by Fuse Science relate directly to the patch market and the Company believes represent several new delivery opportunities. Estradiol, which is a very common estrogen replacement therapy delivered in patch form, was specifically researched documenting delivery through the epidermis in a roll-on application. Some of the other current leading transdermal delivery-based products are Fentanyl for pain management, Clonidine for high blood pressure, Nitroglycerine for chest pain, Lidocaine for nerve pain related to shingles, Nicotine, Testosterone, and the Ethinyl Estradiol and Norelgestromin combination to address pregnancy prevention. It is the Company's belief that it can successfully deliver each of the stated compounds in roll-on form through their proprietary technology.

For more information:

To schedule an interview:

Fuse Science, Inc.

Gus DeQuesada

Investor Relations

Michelsen Advertising

Direct: (305) 503-3873, Ext. 2

C-305-733-1410 / 786-488-7138

Email: ir@fusescience.com

prnews@michelsenadvertising.com

About Fuse Science, Inc.
Fuse Science, Inc. (OTCQB: DROP) is an innovative holding company based in Miami Lakes, Florida. Fuse Science holds the rights to new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents that can now, for the first time, effectively encapsulate and charge many varying molecules in order to produce complete product formulations which can bypass the gastrointestinal tract and enter the blood stream directly either through a topical gel roll-on or alternatively in a concentrated "DROP" form that is simply applied under the tongue. Fuse Science's technology is designed to accelerate conveyance of medicines or nutrients relative to traditional pills and liquids and can enhance how consumers receive these products. Information about Fuse Science is available online at www.fusescience.com and www.poweredbyfuse.com or by calling 305-503-FUSE (3873).

Safe Harbor Statement
Certain statements and information included in this release may constitute "forward-looking statements" as defined in the Federal Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the company to be materially different from any future results, performance or achievements expressed or implied in such statements. Additional discussion of factors that could cause actual results to differ materially from management's projections, estimates and expectations is contained in the Company's SEC filings which can be found at www.sec.gov. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by federal securities laws.

SOURCE Fuse Science, Inc.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->